ux003
Recombinant proteinexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2013 (NCT01856218)
Timeline
Indications
Mechanism of action
- Beta-glucuronidaseINHIBITOR
GUSB inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ux003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02432144 | Phase 3 | Oct 1, 2015 | Sponsor GmbH, Ultragenyx Inc. |
| NCT02418455 | Phase 2 | Jul 1, 2015 | Ultragenyx Inc. |
| NCT02230566 | Phase 3 | Nov 1, 2014 | Florida International University, Ultragenyx Inc., University of California, Irvine, University of California, San Francisco, University of Minnesota |
| NCT02097251 | N/A | Mar 24, 2014 | Northwell Health, Ultragenyx Inc. |
| NCT01856218 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2013 | Ultragenyx Inc., University of Manchester |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ultragenyx Inc. | For profit | 5 | 4 | 3 | 2013 |
| Florida International University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Northwell Health | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2014 |
8 organizations
Page 1 / 1